Document is current
Any future updates will be listed below
-
Authors
Fergus, Kirkpatrick B.
Heise, Rachel S.
Madlensky, Lisa
Fiscalini, Allison
Sabacan, Leah
Theiner, Sarah
Kapoor, Shreya
Soto, Irene A.
Blanco, Amie
Ross, Katherine
Goodman-Gruen, Deborah
Scheuner, Maren
Hu, Donglei
Heditsian, Diane
Brain, Susie
Arasu, Vignesh A.
Kaster, Andrea
Chapa, Lisa
Olopade, Olufunmilayo I.
Eklund, Martin
Tice, Jeffrey A.
Ziv, Elad
van ‘t Veer, Laura
Esserman, Laura J.
Shieh, Yiwey
,
-
Funding
Funding for this research was provided by:
ASCO Young Investigator Award (2023YIA- 413 9977333099)
U.S. Department of Defense (GRANT13922076-BC230196)
National Cancer Institute (R01CA237533, K08CA237829)
Patient-Centered Outcomes Research Institute (PCS-1402-10749)
Breast Cancer Research Foundation (SPEC-22-018)
- License Information
-
More Information
Article History
Received: 20 February 2025
Accepted: 31 July 2025
First Online: 28 August 2025
Declarations
:
: The WISDOM Study received approval from the University of California, San Francisco Institutional Review Board (#15-18234). Participants provided informed consent to participate in the study. All research conformed to the principles of the Helsinki Declaration.
: Not applicable.
: Olufunmilayo Olopade is co-founder and equity shareholder of CancerIQ, and Board Director of 54gene. Laura van ‘t Veer is a stockholder of Agendia and a consultant to Exai Bio Inc. The remaining authors declare that they do not have any competing interests.
